Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Range Change

Score

0.5

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 78 6.0 0.40% 0.66% 11.5% -3.4% 195.7%
SHORT 79 5.2 0.34% 0.50% 5.3% -3.2% -29.4%

Summary

Technical Analysis


The range of the bar gives important information about the strength of weakness of a trend. If buyers are very committed they will be keen to buy and will tend to bid the price up even in the face of some selling pressure. Price will quickly & easily move upward and the move will tend to be significant. As such expanding ranges indicate the either buyers or sellers becoming more committed. Alternatively once the range begins to contract the side in control are losing commitment.

Calculation: Range Today Versus Range Yesterday (RTRY):
1) Expanding ranges on the upside indicates that buyers are increasingly eager;
2) Expanding ranges on the downside indicates that sellers are increasingly eager;
3) Contracting ranges on the upside indicates that buyers are becoming less eager;
4) Contracting ranges on the downside indicates that sellers are becoming less eager;


PROFILE: Ra Pharmaceuticals Inc (RARX)


Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Range Change

Download
Company Close Change(%) Volume Value Signal
ARAY Accuray Incorporated 3.95 7.9 2,162,586 0 NEUTRAL
SYRS Syros Pharmaceuticals 8.2 4.9 153,243 0 NEUTRAL
TRUP Trupanion Inc 33.32 4.2 261,897 0 NEUTRAL
IRTC Irhythm Technologies 86.09 3.8 484,350 0 NEUTRAL
OTIC Otonomy Inc 3.65 3.1 161,652 0 NEUTRAL
VRAY Viewray Inc 3.06 3 3,697,594 0 NEUTRAL
SGEN Seattle Genetics Inc 111.53 2.6 396,484 0 NEUTRAL
ALGN Align Technology 279.31 2.2 795,665 0 NEUTRAL
AMBC Ambac Financial 22.43 1.9 182,363 0 NEUTRAL
NTLA Intellia Therapeutics 14.64 1.9 548,959 0 NEUTRAL